WuXi is back on the Pentagon’s blacklist. The United States Treasury might restrict investments in Chinese biotech. Despite wave after wave of big pharma announcements around partnerships with China, the protectionist voices are taking up more airtime. Where are the winds blowing, and what material impact could this all have?
Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D
Podden och tillhörande omslagsbild på den här sidan tillhör
Endpoints News. Innehållet i podden är skapat av Endpoints News och inte av,
eller tillsammans med, Poddtoppen.
